We were delighted to be able to speak with Lluís Puig (Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain) about novel pathophysiology-based therapeutic agents in the treatment of psoriasis. His full presentation entitled ‘New therapeutic targets based on pathophysiology’ was presented at the EADV Virtual Congress 2020.
Questions
- Could you give us a brief overview of the most well known cytokines in the pathogenesis of psoriasis? (0:13)
- What have we learned about the role of IL-36 in the pathogenesis of plaque psoriasis? (1:20)
- What therapeutic agents targeting IL-36 have been developed? (3:02)
- What other molecules in the IL-1 superfamily may be useful therapeutic targets? (4:22)
Disclosures: Lluís Puig has received consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EADV 2020 Virtual Congress.
